• An Equilibrium Model Estimated on Pharmaceutical Data 

      Dalen, Dag Morten; Locatelli, Marilena; Strøm, Steinar Øivind (Journal article; Peer reviewed, 2018)
      The purpose of this paper is to estimate patients’ and doctors’ responses to prices when making a choice between brand name products and generics. We account for the response of pharmacies to government regulation and to ...
    • Does the identity of the third-party payer matter for prescribing doctors? 

      Dalen, Dag Morten; Locatelli, Marilena; Sorisio, Enrico; Strøm, Steinar (Journal article; Peer reviewed, 2014)
      TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with threeblockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, ...
    • Med forhandlingsmakt skal legemiddelprisene fastsettes 

      Dalen, Dag Morten (Journal article; Peer reviewed, 2020)
      Det kommer stadig nye legemidler på markedet som gjør det mulig å forbedre behandlingen av pasienter med alvorlige sykdommer, men disse kommer ofte med en prislapp som vekker oppsikt. Før slike legemidler kommer inn i det ...
    • Paying for pharmaceuticals: uniform pricing versus two-part tariffs 

      Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2022)
      Two-part pricing (the Netflix model) has recently been proposed instead of uniform pricing for pharmaceuticals. Under two-part pricing the health plan pays a fixed fee for access to a drug at unit prices equal to marginal ...
    • Should pharmaceutical costs be curbed? 

      Brekke, Kurt R.; Dalen, Dag Morten; Strøm, Steinar (Journal article; Peer reviewed, 2012)
      Pharmaceuticals account for almost a fifth of total health spending in OECD-countries. Both pharmaceutical innovations and the aging of the population explain the increasing importance of pharmaceuticals in health care. ...